# Hy2Care

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hy2care-b-v

- Industry: Pharmaceuticals
- Headquarters: Netherlands
- Website: www.hy2care.com
- Total disclosed funding: $4.1M
- Latest round: Series A (Apr 30, 2019)
- Investors on record: 2

## About

Based in the Netherlands, Hy2Care B.V. specializes in innovative medical solutions, particularly the development and commercialization of hydrogel implants aimed at cartilage recovery in joint injuries.Hy2Care B.V. is dedicated to creating advanced medical treatments for cartilage defects. Founded in 2014, the company is based in the Netherlands. The firm has successfully completed three funding rounds, with the latest round occurring on May 14, 2025, raising EUR 4.5 million led by Brightlands Venture Partners, alongside participation from the European Innovation Council and Industriebank LIOF. The firm's leadership includes CEO Leo Smit and founders Chris Cardinaels and Marcel Karperien.Hy2Care® specializes in the development and commercialization of the CartRevive® hydrogel implant, designed to facilitate the functional recovery of cartilage defects in joints. This innovative implant utilizes natural polymers that mimic joint tissue, providing a protective environment for injured areas and promoting natural healing. The CartRevive® implant primarily targets patients suffering from cartilage damage, thereby filling a vital need in the healthcare market. Hy2Care® focuses its sales efforts in Europe and is working towards expansion into the United States, catering to healthcare providers and orthopedic specialists.Hy2Care® generates revenue through direct sales of its CartRevive® hydrogel implant to healthcare providers, including hospitals and orthopedic clinics. The company engages in B2B transactions, forming partnerships with medical institutions for clinical applications. Revenue is structured around one-time sales of the hydrogel implant, which is integrated into surgical procedures for cartilage repair, with pricing based on negotiated contracts with healthcare providers.On May 14, 2025, Hy2Care B.V. secured EUR 4.5 million in venture funding, led by Brightlands Venture Partners. This funding will support the expansion of market reach and further development of the CartRevive hydrogel platform. The company aims to introduce new product designs and launch initiatives targeting specific market expansions, particularly into the United States, enhancing its offerings for orthopedic professionals.

## Funding rounds

- Series A, Apr 30, 2019, $4.1M — Brightlands Venture Partners, ReumaNederland

## Investors

- Brightlands Venture Partners (https://capitalatlas.ai/funds/brightlands-venture-partners) — Series A
- ReumaNederland — Series A